Vol. 97, No. 1, 2013
Issue release date: February 2013
Free Access
Neuroendocrinology 2013;97:35–44
Growth Factors / Receptors
Add to my selection

EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets

Kidd M.a · Schimmack S.a, b · Lawrence B.a · Alaimo D.a · Modlin I.M.a
aGastrointestinal Pathobiology Research Group, Department of Gastroenterological Surgery, Yale University School of Medicine, New Haven, Conn., USA; bUniversity Hospital of General, Visceral and Transplantation Surgery, Heidelberg, Germany
email Corresponding Author


 goto top of outline Key Words

  • CTGF
  • EGFR
  • Neoplasia
  • Neuroendocrine neoplasms
  • TGFα
  • TGFβ

 goto top of outline Abstract

Neuroendocrine neoplasms (NENs) are a heterogeneous family of malignancies whose proliferation is partially dependent on growth factors secreted by the microenvironment and the tumor itself. Growth factors which were demonstrated to be important in experimental models of NENs include EGF (epidermal growth factor), TGF (transforming growth factor) α, TGFβ and CTGF (connective tissue growth factor). EGF and TGFα bind to the EGF receptor to stimulate an intact RAS/RAF/MAPK pathway, leading to the transcription of genes associated with cell proliferation, invasion and metastasis. Theoretically, TGFα stimulation can be inhibited at several points of the MAPK pathway, but success is limited to NEN models and is not evident in the clinical setting. TGFβ1 stimulates TGFβ receptors (TGFβRI and TGFβRII) resulting in inhibition of neuroendocrine cell growth through SMAD-mediated activation of the growth inhibitor P21WAF1/CIP1. Although some NENs are inhibited by TGFβ1, paradoxical growth is seen in experimental models of gastric and small intestinal (SI) NENs. Therapeutic targeting of TGFβ1 in NENs is therefore complicated by uncertainty of the effect of TGFβ1 secretion on the direction of proliferative regulation. CTGF expression is associated with more malignant clinical phenotypes in a variety of cancers, including NENs. CTGF promotes growth in gastric and SI-NEN models, and is implicated as a mediator of local and distant fibrosis caused by NENs of enterochromaffin cell origin. CTGF inhibitors are available, but their anti-proliferative effect has not been tested in NENs. In summary, growth factors are essential for NEN proliferation, and although interventions targeting these proteins are effective in experimental models, only limited clinical efficacy has been identified.

Copyright © 2012 S. Karger AG, Basel

goto top of outline Introduction

Although gastroenteropancreatic (GEP) and bronchopulmonary (BP) neuroendocrine neoplasms (NENs) comprise only ∼2% of all malignancies [1], they are rapidly increasing in incidence and prevalence. These cancers exhibit a wide spectrum of biological and malignant phenotypes and range from neoplasms that are largely ‘benign’, e.g. gastrin-responsive gastric enterochromaffin-like (ECL) cell neoplasms (type 1 gastric ‘carcinoids’) or pancreatic β-cell tumors, to aggressive tumors with a poor prognosis, e.g. pancreatic and colon neuroendocrine cancers, and small-cell lung cancers (SCLC) [1,2]. Apart from gastric NENs that are driven by the hypergastrinemia associated with a low acid state, the etiopathogenesis of NENs is unknown. They are considered to evolve from DNA-damaging events to neuroendocrine committed stem cells while a minority is associated with known inherited menin-related genetic events [1,3].

Overall, this class of neoplasia has not been well studied, and consequently few targeted therapies exist apart from agents that activate somatostatin receptors [4,5]. More recently, other receptors and regulatory pathways have been identified (tyrosine kinases, VEGFR, PGFDR and mTOR) that appear to have some utility as therapeutic targets. For example, both the tyrosine kinase (TK) inhibitor (TKI) sunitinib and the mTOR inhibitor everolimus have been shown to improve progression-free survival in patients with advanced pancreatic NEN although substantial concerns have been raised by rigorous critics of the design of both studies [6,7]. In this review, we examine the EGFR (epidermal growth factor receptor)/TGF (transforming growth factor) α, TGFβ and CTGF (connective tissue growth factor) class of receptors and growth factors as proliferative regulators in GEP- and BP-NENs. This overview focuses on their transcriptional status and expression levels, chromosomal or mutational alterations and signal pathway activation related to NENs. In addition, we describe the biological mechanisms by which NENs modify their microenvironment (peritoneal or valvular fibrosis, and hepatic metastases) and the clinical implications of targeted therapy for this class of growth factors.


goto top of outline EGF/TGFα, EGFR Signaling: Candidate, Multilevel Targets

EGF and TGFα are polypeptides that bind EGFRs activating signal transduction pathways (RAS-RAF-MAPK) that regulate cellular responses to growth signals.

EGF is a 53-amino-acid polypeptide (6-kDA protein) derived from a large precursor molecule, which is proteolytically cleaved to generate the final peptide. EGF is encoded on chromosome 4q25; alternate splicing results in multiple transcript variants. Biologically, EGF is a mitogenic factor regulating growth, proliferation and differentiation of numerous cell types; abnormalities in EGF signaling pathways have been associated with growth and progression of neoplasia [8].

TGFα is a growth factor related to EGF and regulates the same signaling pathways through activation of the same receptors. Co-expression of this 50-amino-acid polypeptide and EGFR confers growth advantage to tumor cells [9]. TGFα is expressed in ∼70–100% of NENs depending on the technique used (immunohistochemistry or Northern blot analysis) [9,10,11,12], and is typically overexpressed in larger rectal NENs with a high proliferative index (measured by Ki-67) [12]. Co-expression of TGFα and EGFR occurs in ∼80% of these neoplasms [12].

EGF and TGFα bind to high-affinity cell surface receptors (EGFR), which are receptor TK members of the ErbB family. Both growth factors specifically bind to the extracellular ligand binding domain of HER1 (ErbB1), and signaling is initiated following receptor homo-/heterodimerization and autophosphorylation by the intracellular kinase domain (fig. 1). Phosphorylation of cytoplasmic substrates initiates a signaling cascade (RAS/RAF/MAPK-ERK) that drives pro-proliferative gene expression, cytoskeletal rearrangement and increased cell proliferation [8]. Somatic mutations in the TK domain of HER1 result in constitutive kinase activity and unregulated pro-proliferation signaling. Such tumors are typically susceptible to TKIs [13].

Fig. 1. EGFR and its growth regulation and inhibition. EGF and TGFα are typical growth factors that transduce growth signals via EGFR (HER1), which is one member of the ErbB family of receptor TKs. Upon ligand binding, HER1 and HER2 dimerize, resulting in autophosphorylation and activation of the intracellular kinase domains, which initiates the cascade of Ras, BRAF and MEKK. The latter phosphorylates MAPK (ERK), which activates transcription factors, including ELK1, positively regulating proliferation and cell survival. This pathway is well studied in a variety of cancers and can be inhibited at a number of levels including the receptor (e.g. by nimotuzumab or cetuximab), the kinase itself (e.g. gefitinib) or at the level of RAF (e.g. sorafenib). The absence of susceptible mutations in EGFR might explain the lack of efficacy of gefitinib in GEP- and BP-NENs. Mutations in TK are associated with cross-activation of the PI3K/AKT/mTOR pathway but this appears only to be a potential relationship and has not been demonstrated in NENs. Mutations in K-Ras occur in ∼2% and may lead to loss of responsiveness to EGFR monoclonal approaches. The efficacy of other agents targeting different levels of this pathway in GEP- and BP-NENs is not currently known. Ras = KRAS mutation.

HER1 (EGFR) and HER4 are expressed in NENs. Immunohistochemical and in situ studies identify HER1 in the majority (80–100%) of small intestinal (SI) and rectal NENs [10,11,12], but it is unclear whether the intracellular domain is expressed [9]. HER4 was expressed in ∼90% of the cases in a mixed group of NENs [14], but its role in tumorigenesis remains unclear. In GEP-NENs, EGFR (HER1) is expressed in gastrinomas [11]. Expression of EGFR is frequent (∼60%) in all lung NENs [15] although SCLCs tend to exhibit low levels of EGFR [16]. At a molecular level, GEP-NENs express EGFR aneusomy (20% of cases) and elevated EGFR copy number (39%) [17]. These results suggest that NENs exhibit an intact, pro-proliferative pathway that may regulate tumor growth and be a potential target for therapy.

A well-described target is the TK domain which can be inhibited by agents such as erlotinib or gefitinib (table 1). These are first-generation agents which have only been shown to be effective in treating lung cancer in individuals that express mutations in EGFR (response rates of 40–71% in mutation-positive tumors vs. 1.1% in EGFR mutation-negative tumors) [18]. Activating somatic mutations are usually present in exons 18, 19 and 21 of HER1. However, in a PCR assessment of 31 BP-NENs, no mutations in the EGFR kinase domain, which were predictive of a response to EGFR-TKIs, were detected [19]. A similar finding was noted in 102 GEP-NENs [17]. EGFR-TK mutations also preferentially activate anti-apoptotic pathways (e.g. PI3K/AKT) [20] suggesting TKIs and AKT inhibitors may be useful under these conditions. However, TK mutations are uncommon in NENs, which suggests that these tumors may not be candidates for this class of agents. A phase II study of gefitinib including 57 patients with GEP-NENs demonstrated that only 1 of 40 evaluable patients achieved a radiological response; however, in 32% time to progression was prolonged [21]. The low efficacy highlights the absence of facilitating EGFR-TK mutations associated with gefitinib activity. This also suggests a combinatorial approach of TKIs and AKT/mTOR inhibitors is unlikely to be efficacious.

Table 1. Growth pathways as potential targets

SCLC cell lines indicate that targeting these very aggressive neoplasms with gefitinib may be potentially effective as MAPK signaling could be inhibited [16]. However, similar to GEP-NENs, EGFR mutations are rare in these tumors (<3%) [22], indicating that current EGFR-TKIs may be ineffective. An alternative mechanism to reduce growth signaling in these neoplasms has been identified by evaluating antagonists of growth hormone-releasing hormone and bombesin since these agents inhibit the expression of the EGF/HER receptor family in SCLC cell lines [23]. Therefore, although EGFR remains a rational target which has already been successfully targeted using monoclonal antibodies (mAbs), e.g. cetuximab in colorectal cancer [24], little is known regarding the therapeutic potential of targeting this receptor in NENs. One caveat while targeting this receptor is the potential for cross-activation of the PI3K/AKT/mTOR pathway, a pro-proliferative pathway that tumor cells may activate when EGFR signaling is inhibited [25].

The EGFR-mediated RAS/RAF/MAPK signaling pathway is usually activated in NENs [26,27]. Immunohistochemistry demonstrates expression of the BRAF activator Rap1 as well as B-Raf itself in GEP-NENs [28], suggesting that one component of EGFR signaling, BRAF itself, might be a candidate target. BRAF, however, is not mutated in either GEP- or BP-NENs [26,29]. In neuroendocrine cell lines, e.g. BON (lymph node metastasis of a pancreatic NEN) and INS-1 (a rat insulinoma cell line), overexpression of Rap1 and B-Raf activated MAPK-ERK2 and ERK-dependent transcription factor Elk-1 has been noted [28]. BAY43-9006 (sorafenib), which suppresses BRAF activity, inhibited growth and induced apoptosis in these cells and suppressed phosphorylation of MAPK-ERK1/2 and its upstream kinase MEK1/2, suggesting targeting EGFR signaling may show some promise in pancreatic-derived NENs [28] (table 1). In non-pancreatic NENs, mutations in KRAS upstream of MAPK have been identified in 3 of 102 NEN samples [17]. All mutations were heterozygous and 2 of them were associated with a lack of response to anti-EGFR mAbs. The relevance of this to current therapeutic strategies is unclear.

Short-term cultured SI-NENs secrete detectable TGFα (400–700 pM), which can be inhibited by targeting sst2 [10]. Exogenous TGFα stimulated growth of these neoplasms in vitro, which could be partially blocked by the use of neutralizing anti-EGFR mAbs [10] suggesting an autocrine-mediated growth-regulatory loop. Other evidence for proliferative roles for these factors comes from studies with BON and KRJ-I (small intestinal enterochromaffin cell-derived NEN cell line) [30]. Both EGF and TGFα (EC50 = 15.8 and 10 ng/ml, respectively) stimulate BON proliferation, while only TGFα (EC50 = 0.63 ng/ ml) stimulates KRJ-I proliferation [31]. Targeting the stress-responsive molecular chaperone Hsp90 with 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) reduces EGFR expression in a lung cell line (NCI-H727) [17] providing a further potential avenue for investigation.

In the Mastomys animal model of gastric NENs (ECL cell tumors), the proliferative effect of TGFα on ECL cells is specifically amplified during the development of gastric mucosal hyperplasia [32] when TGFα and EGFR expression increased in transforming gastric ECL cells [32]. This suggests that during low acid-induced hypergastrinemia, expression of TGFα and EGFR may constitute an autocrine regulatory mechanism in ECL cell tumor transformation.

In the RIP1-Tag2 (RT2) mouse model of pancreatic NENs, EGFR inhibitor treatment (erlotinib) resulted in a reduced growth rate of tumors with no abnormalities in EGFR [33]. This was associated with increased apoptosis and reduced neovascularization. These effects appeared to be mediated by TGFα (apoptosis) and HB-EGF (angiogenesis; through signaling in the tumor microenvironment), suggesting more dynamic roles for a non-mutated EGFR in NEN pathogenesis.

These data suggest that proliferation in both GEP- and BP-NENs is stimulated by growth-regulatory factors such as EGF and TGFα, which function through an intact EGFR to regulate the RAS/RAF/MAPK signaling pathway. The source of TGFα appears to be autocrine. Despite making an attractive therapeutic target, at multiple levels, there is no currently available agent in clinical use for NENs.


goto top of outline The TGFβ1 Superfamily: Positive and Negative Roles in Proliferation

The TGFβ superfamily encodes a range of secreted proteins, including TGFβ1, TGFβ2 and TGFβ3 as well as inhibins and bone morphogenic proteins (BMPs) [34]. TGFβs are effective and ubiquitous mediators of cell growth via interaction with TGFβ receptors (TGFβRI and TGFβRII). They are considered potent inhibitors of normal cell growth in the physiological setting, but cells undergoing malignant transformation become either partly or completely resistant to TGFβ growth inhibition. In fact, there is growing evidence that during the later stages of cancer development, TGFβ has a paradoxical pro-proliferative effect. TGFβ is actively secreted by tumor cells and contributes to cell growth, invasion and metastasis while decreasing host-tumor immune response [35]. The majority of work in NENs has focused on TGFβ1.

TGFβ1, which is encoded on Chr19q13.1, is a 44.3-kDa protein that is usually secreted as in an inactive form consisting of a homodimer non-covalently linked to a LAP (latency-associated peptide) homodimer. Additional processing to release the active form involves matrix metalloproteinases, alterations in pH, production of reactive oxygen species or the activity of thrombospondin-1 [34]. Active TGFβ1 binds to TGFβRII, which form heterodimers with TGFβRI. This results in receptor-mediated serine-threonine kinase activity with phosphorylation of the SMAD family of transcription factors and activation/inhibition of various genes, depending on the state of cell transformation (fig. 2) [34,35].

Fig. 2. TGFβR and its growth regulation and inhibition. Under physiological conditions, activation of TGFβRI and TGFβRII following TGFβ binding results in G1 cell cycle arrest (through the inhibitory activity of P21WAF1/CIP1; central panel). These effects are mediated via the serine threonine kinase of the receptor complex, SMAD2–SMAD4 activation (through phosphorylation) and nuclear targeting of these transcription factors. BMP receptors are also associated with activation of the SMAD cascade. In NENs (and other tumors, e.g. glioblastomas), nuclear targeting of SMAD is inhibited and cross-activation of growth-stimulatory pathways occur including the RAS/RAF/MAPK signaling pathway and the PI3K/AKT/mTOR pathways. Under these circumstances, TGFβ switches to a pro-proliferative role. No preclinical or clinical studies have been conducted using TGFβRI inhibitors in NENs, while other studies have demonstrated the utility of targeting the mTOR pathway. Solid lines = Good evidence for pathway activation; dotted lines = incomplete evidence.

At a signaling pathway level, NENs express SMADs (SMAD2–SMAD4), but no SMAD4 mutations have been identified in SI-NENs [36]. In addition, SMAD3 has not been identified as a tumor suppressor; although loss of heterozygosity has been noted for markers in ∼20% of NENs, no acquired clonal mutations, insertions or microdeletions in SMAD3 were detected [37]. NENs exhibit variable expression of the TGFβ1 cytostatic program target protein P21WAF1/CIP1 [38,39] and also frequently express c-Myc [40], a TGFβ1 pathway antagonist.

Immunohistochemical studies identify TGFβ1 and its receptors in the majority of GEP-NENs [11,41,42,43], suggesting these lesions may be a biological target for paracrine and autocrine antimitogenic actions of this growth factor. It should be noted that lesions exhibit variable expression of TGFβRII [44] but do not exhibit microsatellite instabilities (leading to early termination) in this receptor.

Three studies have examined the role of TGFβ in NEN cell lines. In BON cells, TGFβ1 treatment resulted in transactivation of a TGFβ-responsive reporter construct as well as inhibition of c-Myc and induction of P21WAF1/CIP1 expression [42]. TGFβ1 also inhibited anchorage-dependent and independent growth in a time- and dose-dependent manner [42], leading to G1 growth arrest without evidence of apoptosis [42]. Functional inactivation of endogenous TGFβ1 revealed the existence of an autocrine anti-proliferative loop in BON cells.

In another study, comparing normal SI enterochromaffin cells with KRJ-I cells, the growth of normal cells could be inhibited by TGFβ1 while KRJ-I cells lost this TGFβ1-mediated cytostasis and were induced to proliferate by TGFβ1 [45]. Additional examination of the TGFβ1 pathway demonstrated low expression levels (mRNA and protein) of non-mutated TGFβRII, phosphorylatable SMAD2 (indicating an intact TGFβ1:TGFβRII signaling) but absent nuclear targeting of pSMAD2. These data suggest that TGFβ1-mediated signal transduction in this cell line, as in glioma cell lines [46], is blocked at the level of SMAD nuclear translocation. This phenomenon was specifically associated with increased expression of the inhibitor of SMAD nuclear translocation, SMAD7, down-regulated p21WAF1/CIP1 transcription and increased expression of c-Myc as well as phosphorylation and cross-activation of ERK1/2 and downstream activation of the malignancy-defining genes MTA1 with loss of E-cadherin. These studies identify that SI-NENs, unlike pancreatic NENs, do not express a TGFβ1-mediated autocrine anti-proliferative loop and that this growth factor may be involved in regulating the metastatic phenotype [45].

In two other studies, TGFβRII was examined in SCLC cell lines and in 80–100% identified to be expressed at low levels [47,48]. This lack or absence of TGFβRII mRNA was not due to either mutations or hypermethylation of the promoter or gene [47,48]. These findings indicate that inactivation of the TGFβ signaling pathway by the loss of TGFβRII gene expression may be common to SCLCs, and these tumors, like SI-NENs, may be resistant to TGFβ1-mediated growth inhibition.

Therapeutic targeting of TGFβ is complicated by the variable anti- or pro-growth effects in different NENs. However, in cases where tumor growth is driven by TGFβ production, three approaches have been developed to inhibit TGFβ signaling: inhibitors of TGFβR, antisense oligonucleotides or mAbs to inhibit ligand-receptor interactions [34,49]. Several agents (e.g. SD-208) have been developed that target receptor kinase activity and exhibit utility in limiting tumor invasion and metastasis in both pancreatic adenocarcinoma and melanoma nude mouse models [50,51] (table 1). Since no clinical data are currently available, it is unclear whether they could be effective in GEP-NENs. An alternative approach may be TGFβ-antisense, which has shown promise both in preclinical (rat glioma models) [52,53] and early clinical trials (high-grade gliomas) [54]. However, TGFβ-antisense agents have not been studied in NEN cell lines, and like TGFβ kinase inhibitors, their utility remains to be established.

In summary, the TGFβ superfamily is an important regulator of growth in NENs. Although it exhibits uniform inhibition of cell growth in the normal physiological setting, NEN models show mechanisms of escape from TGFβ-mediated growth inhibition. Further, TGFβ appears to encourage growth in NENs, some of which exhibit high levels of TGFβ and TGFβR. To the best of our knowledge, therapeutic targeting of TGFβ has not been attempted in NENs.


goto top of outline CTGF: A Proliferative Regulator and Role in Fibrosis

CTGF, IGFBP (insulin growth factor binding protein) or CCN2, is a 38-kDa, cysteine-rich secreted protein coded by chromosome 6q23.1 [55,56]. This is one of the immediate-early response genes expressed after induction by growth factors or certain oncogenes [56]. CTGF has been identified in a variety of tumors of mesenchymal, epithelial and lymphoid origin [56], and expression levels of transcripts and/or protein are positively correlated with bone metastasis in breast cancer [57], glioblastoma growth [58], poor prognosis in esophageal adenocarcinoma [59], aggressive behavior of pancreatic cancer cells [60] and invasive melanoma [61]. This gene is also overexpressed in a mouse transgenic model of gastric neuroendocrine cell carcinoma [62].

goto top of outline CTGF and Proliferation

CTGF signaling has been studied in NEN tumor models. In animal studies (Mastomys model), CTGF transcript and protein were overexpressed in gastric ECL tumor cells compared to normal ECL cells [63]; this growth factor stimulated tumor ECL cell proliferation but not normal cell proliferation and synergized the proliferative effects of EGF under in vitro conditions [63]. These effects were mediated via ERK1/2 phosphorylation and could be reversed by pharmacological inhibition of this pathway with PD98059 (fig. 3) [63]. These data suggested CTGF may play a role as a regulator of ECL cell proliferation. A follow-up in vivo study, where the CCK2 receptor was inhibited during hypergastrinemia induced by the irreversible histamine 2 receptor antagonist loxtidine, identified a reduction in CTGF levels (and animals did not develop tumors), confirming that this growth factor played a role in tumor ECL cell proliferation [64]. A proliferative role for CTGF has been confirmed in the SI-NEN cell lines; KRJ-I responded with proliferation to CTGF (EC50 = 0.002 ng/ml), but no effect was noted on BON cell proliferation and little is known regarding the role of CTGF in the mechanistic regulation of BP-NEN proliferation [31].

Fig. 3. CTGF regulations and fibrosis: CTGF binds its receptor CTGFR but may also bind IGF receptors (IGFRs). Activation of CTGFR augments both IGFR and EGFR signaling pathways. The former is associated with AKT/GSK3 activation and the production of collagen – a key event in fibrosis – the latter with growth-mediated cell proliferation. While monoclonal antibodies against CTGF have efficacy in preclinical and clinical studies of fibrotic diseases, targeting this receptor has not been undertaken in NENs.

CTGF signaling has also been studied in NENs. In gastric NENs, expression of CTGF mRNA and protein specifically differentiated type 1 and 2 ‘gastrin-dependent’ lesions from type 3 ‘gastrin-independent’ neoplasms [63], with overexpression of CTGF in the more malignant type 3 tumors [63] suggesting that CTGF may be related to autonomous (non-gastrin-responsive) tumor growth.

goto top of outline CTGF and Fibrosis

In addition to functioning as a growth factor for NENs, CTGF has a fundamental role in mediating fibrosis associated with SI-NENs. In particular, SI-NENs overexpress CTGF mRNA and synthesize CTGF protein, which was significantly elevated in the tumors and blood of patients with clinically documentable fibrosis [65]. CTGF immunoreactivity was identified in >50% of tumor cells in 100% of lesions (n = 42) with less expression in pancreatic NENs (14%) and BP-NENs (20%) [66]. Protein bands corresponding to full-length CTGF (36–42 kDa) were detected as well as immunoreactive cells that expressed α-SMA (smooth muscle actin) in adjacent mucosa [66]. These results confirm a potential role for CTGF in myofibroblast-mediated fibrosis associated with these neoplasms, and indicate that CTGF may be a therapeutic target. Further, plasma CTGF is strongly related to valvular and mural carcinoid heart disease [67]: a significant inverse correlation was noted between right ventricular function and plasma CTGF levels; patients with reduced cardiac function had higher plasma CTGF levels, and CTGF ≥77 µg/l was identified as an independent predictor of reduced cardiac function (88% sensitivity and 69% specificity) [67]. In addition, plasma CTGF was elevated in patients with moderate-to-severe valvular regurgitation [67]. Both these studies found that CTGF may play a role in NEN-related mesenteric and cardiac fibrosis. The detection of elevated CTGF blood levels may provide a diagnostic opportunity to predict the development of fibrosis and preempt its local and systemic complications.

CTGF has been considered an attractive therapy for fibrosis-associated diseases. Neutralizing and scFv (single-chain variable fragment) antibodies against CTGF have shown efficacy in mouse models of fibrosis [68,69]. Similarly, a phase I study in microalbuminuric diabetic kidney disease (a progressive fibrotic disease) using a human mAb against CTGF (FG-3019) identified that the urinary albumin/creatinine ratio (a marker of efficacy) was significantly decreased [70]. However, no studies have been conducted in NENs for fibrosis-associated diseases. The potential efficacy of this approach has been demonstrated in mouse xenograft studies with pancreatic cancer cells [71] where FG-3019 abolished CTGF-dependent tumor growth and inhibited lymph node metastases without any toxicity in normal tissue [71] (table 1). Alternatively, as this protein is a downstream target of TGFβ1 [56], inhibiting the latter signaling pathway may have efficacy in reducing CTGF expression and diminishing its proliferative activity.

In summary, the presence of CTGF in tumors is associated with a malignant phenotype across a range of cancers. CTGF is present in many NENs and encourages growth in SI-NEN cell lines and a gastric NEN animal model. The presence of CTGF is associated with more malignant phenotypes in clinical gastric and SI-NENs. As well as encouraging proliferation, CTGF is a pivotal mediator of NEN-associated fibrosis.


goto top of outline Conclusion

Proliferation of GEP- and BP-NENs is responsive to the growth factors EGF, TGFα, TGFβ and CTGF, and therefore may be susceptible to therapeutics that target these receptors or associated signaling pathways, e.g. BRAF/MAPK. Despite evidence from cell lines, animal models and clinical samples, there are no good examples of the use of receptor-tailored pharmacotherapies that target these growth factors in NENs. The multiple and overlapping signaling pathways that characterize GEP-NENs (fig. 4), however, suggest targeting these tumors at a number of levels may be required to provide efficacy.

Fig. 4. Overview of common signal pathway activation in GEP-NENs. The signaling pathways activated either directly or due to cross-activation are MAPK and AKT/mTOR signaling. All ligands signal via these pathways to positively regulate proliferation and metastasis. Separately, an event that only occurs in a subset of GEP-NENs (SI-NENs), TGFβ and CTGF activate fibrogenic pathways resulting in local (peritoneal) or distant (cardiac) disease. The common activation of RAS/RAF signaling suggests that therapeutic agents that target elements of this pathway may be potentially effective in NENs.


goto top of outline Acknowledgement

M.K. is supported by NIH: DK080871, S.S. by the Deutsche Forschungsgemeinschaft: SCHI 1177/1-1 and B.L. by the Murray Jackson Clinical Fellowship from the Genesis Oncology Trust Auckland, New Zealand.

 goto top of outline References
  1. Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM: The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 2011;396:273–298.
  2. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM: Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5–21.
  3. Thakker RV: Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 2010;24:355–370.
  4. Lawrence B, Gustafsson BI, Kidd M, Modlin I: New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin North Am 2010;39:615–628.
  5. Modlin IM, Pavel M, Kidd M, Gustafsson BI: Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169–188.
  6. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501–513.
  7. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–523.
  8. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31–53.
  9. Krishnamurthy S, Dayal Y: Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids. Am J Surg Pathol 1997;21:327–333.
  10. Nilsson O, Wangberg B, Kolby L, Schultz GS, Ahlman H: Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int J Cancer 1995;60:645–651.
  11. Wulbrand U, Wied M, Zofel P, Goke B, Arnold R, Fehmann H: Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 1998;28:1038–1049.
  12. Shimizu T, Tanaka S, Haruma K, et al: Growth characteristics of rectal carcinoid tumors. Oncology 2000;59:229–237.
  13. Pander J, Guchelaar HJ, Gelderblom H: Pharmacogenetics of small-molecule tyrosine kinase inhibitors: optimizing the magic bullet. Curr Opin Mol Ther 2010;12:654–661.
  14. Srirajaskanthan R, Shah T, Watkins J, Marelli L, Khan K, Caplin ME: Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours. Oncol Rep 2010;23:909–915.
  15. Rusch VW, Klimstra DS, Venkatraman ES: Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996;62:798–809, discussion 09–10.
  16. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K: Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib (‘Iressa’, ZD1839). Oncol Rep 2004;12:1053–1057.
  17. Gilbert JA, Adhikari LJ, Lloyd RV, et al: Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer 2010;17:623–636.
  18. Modlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S, Kidd M: The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg 2011;396:1145–1156.
  19. Rickman OB, Vohra PK, Sanyal B, et al: Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res 2009;15:3315–3324.
  20. Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R: Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 2001;44:338–348.
  21. Drozdov I, Kidd M, Nadler B, et al: Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer 2009;115:1638–1650.
  22. Modlin IM, Gustafsson BI, Drozdov I, Nadler B, Pfragner R, Kidd M: Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors. Ann Surg Oncol 2009;16:487–498.
  23. Kanashiro CA, Schally AV, Varga JL, Hammann B, Halmos G, Zarandi M: Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. Cancer Lett 2005;226:123–131.
  24. Garrett CR, Eng C: Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 2011;11:937–949.
  25. Yoon YK, Kim HP, Han SW, et al: Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 2009;8:2526–2536.
  26. Tannapfel A, Vomschloss S, Karhoff D, et al: BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol 2005;123:256–260.
  27. Perren A, Schmid S, Locher T, et al: BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 2004;11:855–860.
  28. Karhoff D, Sauer S, Schrader J, et al: Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 2007;85:45–53.
  29. Yamamoto H, Shigematsu H, Nomura M, et al: PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913–6921.
  30. Modlin IM, Kidd M, Pfragner R, Eick GN, Champaneria MC: The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab 2006;91:2340–2348.
  31. Siddique ZL, Drozdov I, Floch J, et al: KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model. Neuroendocrinology 2009;89:458–470.
  32. Tang LH, Modlin IM, Lawton GP, Kidd M, Chinery R: The role of transforming growth factor alpha in the enterochromaffin-like cell tumor autonomy in an African rodent mastomys. Gastroenterology 1996;111:1212–1223.
  33. Nolan-Stevaux O, Truitt MC, Pahler JC, et al: Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes. Genes Cancer 2010;1:125–141.
  34. Massague J: TGFβ in cancer. Cell 2008;134:215–230.
  35. Padua D, Massague J: Roles of TGFβ in metastasis. Cell Res 2009;19:89–102.
  36. Lollgen RM, Hessman O, Szabo E, Westin G, Akerstrom G: Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer 2001;92:812–815.
  37. Shattuck TM, Costa J, Bernstein M, Jensen RT, Chung DC, Arnold A: Mutational analysis of Smad3, a candidate tumor suppressor implicated in TGF-beta and menin pathways, in parathyroid adenomas and enteropancreatic endocrine tumors. J Clin Endocrinol Metab 2002;87:3911–3914.
  38. Guo SS, Wu X, Shimoide AT, Wong J, Sawicki MP: Anomalous overexpression of p27(Kip1) in sporadic pancreatic endocrine tumors. J Surg Res 2001;96:284–288.
  39. Kawahara M, Kammori M, Kanauchi H, et al: Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumours. Eur J Surg Oncol 2002;28:140–146.
  40. Wang D, Johnson C, Buchanan K: Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer 1997;80:668–675.
  41. Chaudhry A, Oberg K, Gobl A, Heldin CH, Funa K: Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res 1994;14:2085–2091.
  42. Wimmel A, Wiedenmann B, Rosewicz S: Autocrine growth inhibition by transforming growth factor beta-1 (TGFβ-1) in human neuroendocrine tumour cells. Gut 2003;52:1308–1316.
  43. Chaudhry A, Funa K, Oberg K: Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993;32:107–114.
  44. Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM: Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer 2005;103:229–236.
  45. Kidd M, Modlin IM, Pfragner R, et al: Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-β1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1. Cancer 2007;109:2420–2431.
  46. Zhang L, Sato E, Amagasaki K, Nakao A, Naganuma H: Participation of an abnormality in the transforming growth factor-beta signaling pathway in resistance of malignant glioma cells to growth inhibition induced by that factor. J Neurosurg 2006;105:119–128.
  47. Hougaard S, Norgaard P, Abrahamsen N, Moses HL, Spang-Thomsen M, Skovgaard Poulsen H: Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines. Br J Cancer 1999;79:1005–1011.
  48. de Jonge RR, Garrigue-Antar L, Vellucci VF, Reiss M: Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. Oncol Res 1997;9:89–98.
  49. Nagaraj NS, Datta PK: Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 2010;19:77–91.
  50. Dhawan M, Selvaraja S, Duan ZH: Application of committee kNN classifiers for gene expression profile classification. Int J Bioinform Res Appl 2010;6:344–352.
  51. Mohammad KS, Javelaud D, Fournier PG, et al: TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 2011;71:175–184.
  52. Akard LP, Wang YL: Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners. Clin Lymphoma Myeloma Leuk 2011;11:385–395.
  53. Milas M, Shin J, Gupta M, et al: Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann Surg 2010;252:643–651.

    External Resources

  54. Aziz KJ: Tumor markers: reclassification and new approaches to evaluation. Adv Clin Chem 1998;33:169–199.
  55. de Winter P, Leoni P, Abraham D: Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein. Growth Factors 2008;26:80–91.
  56. Moussad EE, Brigstock DR: Connective tissue growth factor: what’s in a name? Mol Genet Metab 2000;71:276–292.
  57. Kang Y, Siegel PM, Shu W, et al: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537–549.
  58. Pan LH, Beppu T, Kurose A, et al: Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma. Neurol Res 2002;24:677–683.
  59. Koliopanos A, Friess H, di Mola FF, et al: Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 2002;26:420–427.
  60. Wenger C, Ellenrieder V, Alber B, et al: Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 1999;18:1073–1080.
  61. Kubo M, Kikuchi K, Nashiro K, et al: Expression of fibrogenic cytokines in desmoplastic malignant melanoma. Br J Dermatol 1998;139:192–197.
  62. Syder AJ, Karam SM, Mills JC, et al: A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype. Proc Natl Acad Sci USA 2004;101:4471–4476.
  63. Kidd M, Modlin IM, Eick GN, Camp RL, Mane SM: Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. Am J Physiol Gastrointest Liver Physiol 2007;292:G191–G200.
  64. Kidd M, Siddique ZL, Drozdov I, et al: The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regul Pept 2010;162:52–60.
  65. Kidd M, Modlin IM, Shapiro MD, et al: CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol 2007;13:5208–5216.
  66. Cunningham JL, Tsolakis AV, Jacobson A, Janson ET: Connective tissue growth factor expression in endocrine tumors is associated with high stromal expression of alpha-smooth muscle actin. Eur J Endocrinol 2010;163:691–697.
  67. Bergestuen DS, Gravning J, Haugaa KH, et al: Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors. BMC Cancer 2010;10:6.
  68. Wang X, Wu G, Gou L, et al: A novel single-chain-Fv antibody against connective tissue growth factor attenuates bleomycin-induced pulmonary fibrosis in mice. Respirology 2011;16:500–507.
  69. Ikawa Y, Ng PS, Endo K, et al: Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-induced mouse fibrosis. J Cell Physiol 2008;216:680–687.
  70. Drozdov I, Tsoka S, Ouzounis CA, Shah AM: Genome-wide expression patterns in physiological cardiac hypertrophy. BMC Genomics 2010;11:557.
  71. Zampetaki A, Kiechl S, Drozdov I, et al: Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010;107:810–817.

 goto top of outline Author Contacts

Irvin M. Modlin
Department of Gastroenterological Surgery
Yale University School of Medicine, 333 Cedar Street
PO Box 208062, New Haven, CT 06520-8062 (USA)
Tel. +1 203 785 5429, E-Mail imodlin@optonline.net

 goto top of outline Article Information

Received: July 7, 2011
Accepted after revision: November 6, 2011
Published online: June 15, 2012
Number of Print Pages : 10
Number of Figures : 4, Number of Tables : 1, Number of References : 71

 goto top of outline Publication Details

Neuroendocrinology (International Journal for Basic and Clinical Studies on Neuroendocrine Relationships)

Vol. 97, No. 1, Year 2013 (Cover Date: February 2013)

Journal Editor: Millar R.P. (Edinburgh)
ISSN: 0028-3835 (Print), eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.